CDMO Capabilities
We provide drug substance development and manufacturing services across the entire lifecycle — helping you seamlessly transition from early development and clinical trials to commercial GMP supply.
Robust process development and manufacturing for complex, high value APIs across clinical and commercial stages — including GMP manufacturing for regulated markets.
Integrated peptide development and manufacturing solutions supporting early phase programs, clinical trials, and commercial supply using flexible technology platforms.
Tailored development of non infringing routes for complex molecules, with a focus on impurity control, reproducibility, and scalability for both clinical and commercial requirements.
From route scouting and feasibility to scale-up for clinical trials manufacturing, ensuring a smooth transition into validated GMP manufacturing.
Global standard GMP manufacturing (USFDA & EU GMP compliant) supporting Phase I–III clinical supply as well as long term commercial production.
Why Partner with Neuland
A trusted partner for innovators seeking reliable CDMO pharma manufacturing, clinical development support, and scalable commercial supply.
- CDMO support from early phase programs, clinical trials to cGMP manufacturing
- cGMP manufacturing compliant with USFDA, EMA, PMDA, and global regulatory standards
- Proven experience supporting global biotech and pharma companies across development stages
- Strong expertise in complex chemistries, challenging syntheses, and impurity control
- Scalable development using QbD and DoE principles to lifecycle risks
Evaluate Your Molecule With Us
Discuss your clinical trials manufacturing, scale up, or GMP manufacturing requirements with our scientific experts.
Whether you're looking to outsource drug manufacturing, optimize your process, or scale to commercial supply — we provide the expertise and infrastructure to support your program.
Confidential technical discussion • No obligation • NDA available on request
Case Studies: Solving complex development & scale‑Up challenges
